Literature DB >> 29785771

Safety and efficacy of apixaban for routine thromboprophylaxis in myeloma patients treated with thalidomide- and lenalidomide-containing regimens.

Neill P F Storrar1, Abhinav Mathur1, Peter R E Johnson1, P Huw Roddie1.   

Abstract

Entities:  

Keywords:  anticoagulants; direct oral anticoagulants; immunomodulatory drugs; multiple myeloma; thrombosis

Mesh：

Substances：

Year:  2018        PMID： 29785771     DOI： 10.1111/bjh.15392

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  5 in total

1.  Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials.

Authors:  Charlotte A Bradbury; Zoe Craig; Gordon Cook; Charlotte Pawlyn; David A Cairns; Anna Hockaday; Andrea Paterson; Matthew W Jenner; John R Jones; Mark T Drayson; Roger G Owen; Martin F Kaiser; Walter M Gregory; Faith E Davies; J Anthony Child; Gareth J Morgan; Graham H Jackson
Journal:  Blood       Date:  2020-08-27       Impact factor: 22.113

2.  Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.

Authors:  Anne Ws Rutjes; Ettore Porreca; Matteo Candeloro; Emanuele Valeriani; Marcello Di Nisio
Journal:  Cochrane Database Syst Rev       Date:  2020-12-18

Review 3.  Potential mechanisms of resistance to current anti-thrombotic strategies in Multiple Myeloma.

Authors:  Claire Comerford; Siobhan Glavey; Jamie M O'Sullivan; John Quinn
Journal:  Cancer Drug Resist       Date:  2022-03-07

Review 4.  The role of VWF/FVIII in thrombosis and cancer progression in multiple myeloma and other hematological malignancies.

Authors:  Claire Comerford; Siobhan Glavey; John Quinn; Jamie M O'Sullivan
Journal:  J Thromb Haemost       Date:  2022-06-23       Impact factor: 16.036

Review 5.  The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma.

Authors:  Maximilian Merz; Tobias Dechow; Mithun Scheytt; Christian Schmidt; Bjoern Hackanson; Stefan Knop
Journal:  Ann Hematol       Date:  2020-04-16       Impact factor: 3.673
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.